https://www.selleckchem.com/
g techniques are needed. Clinicaltrials.gov identifier NCT03727464. Clinicaltrials.gov identifier NCT03727464. The treatment of haemorrhagic shock is a challenging task. Colloids have been regarded as standard treatment, but their safety and benefit have been the subject of controversial debates. Negative effects, including renal failure and increased mortality, have resulted in restrictions on their administration. The cerebral effects of different infusion regimens are largely unknown. The current study investigated the impact of gelatine-polysuccinate, h
Mi piace
Commento
Condividi
